Vaxart Phase 1 norovirus vaccine data: 141% (GI.1) and 94% (GII.4) antibody titer increases vs first-gen

Vaxart, Inc.

Second-gen constructs showed 141% increase in GI.1 and 94% increase in GII.4 NBAA titers vs first-gen at high dose, statistically significant.
All constructs safe and well-tolerated; no vaccine-related serious adverse events reported.
Vaxart plans Phase 2b as early as H2 2025, Phase 3 potentially in 2026, pending partnership/funding.
Company believes data supports potential for first-in-class or best-in-class oral norovirus vaccine.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.